| Denumire comercială | DCI | Forma farmaceutică | Cod ATC | Cod CIM | Firma / țara deținătoare APP |  |
 |
 |
 |
 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| OCTAGAM 10% | IMUNOGLOBULINA NORMALA PT. ADM. INTRAVASCULARA | SOL. PERF. | J06BA02 | W65903004 | OCTAPHARMA (IP) SPRL - BELGIA | ||||||
| OCTAGAM 10% | IMUNOGLOBULINA NORMALA PT. ADM. INTRAVASCULARA | SOL. PERF. | J06BA02 | W65903005 | OCTAPHARMA (IP) SPRL - BELGIA | ||||||
| OCTAGAM 10% | IMUNOGLOBULINA NORMALA PT. ADM. INTRAVASCULARA | SOL. PERF. | J06BA02 | W65903006 | OCTAPHARMA (IP) SPRL - BELGIA | ||||||
| OCTAGAM 10% | IMUNOGLOBULINA NORMALA PT. ADM. INTRAVASCULARA | SOL. PERF. | J06BA02 | W65903007 | OCTAPHARMA (IP) SPRL - BELGIA | ||||||
| OCREVUS 920 mg | OCRELIZUMABUM | SOL. INJ. | L04AG08 | W70385001 | ROCHE REGISTRATION GMBH - GERMANIA | X | |||||
| OCREVUS 300 mg | OCRELIZUMABUM | CONC. PT. SOL. PERF. | L04AG08 | W64485001 | ROCHE REGISTRATION GMBH - GERMANIA | X | |||||
| OBIZUR 500 U | SUSOCTOCOG ALFA | PULB.+SOLV. PT. SOL. INJ. | B02BD14 | W66930001 | BAXALTA INNOVATIONS GMBH - AUSTRIA | X | |||||
| OBIZUR 500 U | SUSOCTOCOG ALFA | PULB.+SOLV. PT. SOL. INJ. | B02BD14 | W66930002 | BAXALTA INNOVATIONS GMBH - AUSTRIA | X | |||||
| OBIZUR 500 U | SUSOCTOCOG ALFA | PULB.+SOLV. PT. SOL. INJ. | B02BD14 | W66930003 | BAXALTA INNOVATIONS GMBH - AUSTRIA | X | |||||
| NYVEPRIA 6 mg | PEGFILGRASTIMUM | SOL. INJ. | L03AA13 | W69561001 | PFIZER EUROPE MA EEIG - BELGIA | X | |||||
| NUWIQ 500UI | SIMOCTOCOG ALFA (FACTOR VIII DE COAGULARE) | PULB.+SOLV. PT. SOL. INJ. | B02BD02 | W61473001 | OCTAPHARMA AB - SUEDIA | X | |||||
| NUWIQ 250UI | SIMOCTOCOG ALFA (FACTOR VIII DE COAGULARE) | PULB.+SOLV. PT. SOL. INJ. | B02BD02 | W61472001 | OCTAPHARMA AB - SUEDIA | X | |||||
| NUWIQ 2000UI | SIMOCTOCOG ALFA (FACTOR VIII DE COAGULARE) | PULB.+SOLV. PT. SOL. INJ. | B02BD02 | W61475001 | OCTAPHARMA AB - SUEDIA | X | |||||
| NUWIQ 1000UI | SIMOCTOCOG ALFA (FACTOR VIII DE COAGULARE) | PULB.+SOLV. PT. SOL. INJ. | B02BD02 | W61474001 | OCTAPHARMA AB - SUEDIA | X | |||||
| NUVARING 0,120 mg/0,015 mg per 24 de ore | COMBINATII (ETONOGESTRELUM+ETINILESTRADIOLUM) | SIST. CU CEDARE VAGINALA | G02BB01 | W68335001 | ORGANON BIOSCIENCES S.R.L. - ROMANIA | ||||||
| NUVARING 0,120 mg/0,015 mg per 24 de ore | COMBINATII (ETONOGESTRELUM+ETINILESTRADIOLUM) | SIST. CU CEDARE VAGINALA | G02BB01 | W68335002 | ORGANON BIOSCIENCES S.R.L. - ROMANIA | ||||||
| NUVARING 0,120 mg/0,015 mg per 24 de ore | COMBINATII (ETONOGESTRELUM+ETINILESTRADIOLUM) | SIST. CU CEDARE VAGINALA | G02BB01 | W68335003 | ORGANON BIOSCIENCES S.R.L. - ROMANIA | ||||||
| NUVARING 0,120 mg/0,015 mg per 24 de ore | COMBINATII (ETONOGESTRELUM+ETINILESTRADIOLUM) | SIST. CU CEDARE VAGINALA | G02BB01 | W68335004 | ORGANON BIOSCIENCES S.R.L. - ROMANIA | ||||||
| NUTROPINAq 10 mg/2 ml | SOMATROPINUM | SOL. INJ. | H01AC01 | W55322001 | IPSEN PHARMA - FRANTA | X | |||||
| NUTROPINAq 10 mg/2 ml | SOMATROPINUM | SOL. INJ. | H01AC01 | W55322002 | IPSEN PHARMA - FRANTA | X |
ANMDMR - Nomenclatorul medicamentelor pentru uz uman